Where Will Vaxart Be in 1 Year?

Jason Hawthorne, The Motley Fool
·4-min read
Where Will Vaxart Be in 1 Year?

Vaxart (NASDAQ: VXRT) has a plan to address the challenge, but a recent phase 1 readout crushed the stock. When Vaxart released the preliminary data from its phase 1 trial for VXA-CoV2-1, the company's oral COVID-19 tablet vaccine candidate, the headline of the press release touted positive results. Management went so far as to express increased confidence in the drug and in the tablet vaccine platform overall.